Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Patritumab [INN]
RN: 1262787-83-6
UNII: 86780VJI1Q


  • An anti-HER3 monoclonal antibody; in phase I clinical trials for treatment of advanced solid tumors.

    NCI: A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds to and inhibits HER3 activation, which may result in inhibition of HER3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do. (NCI Thesaurus)
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Patritumab [INN]


  • Patritumab
  • UNII-86780VJI1Q

Registry Numbers

CAS Registry Number

  • 1262787-83-6


  • 86780VJI1Q

System Generated Number

  • 1262787836